Scantek Medical of Denville, NJ, last month terminated its four-year licensing agreement with HumaScan of Cranford, NJ. By ending its deal with HumaScan, Scantek regains the rights to market and sell its BreastAlert Differential Temperature Sensor device
Scantek Medical of Denville, NJ, last month terminated its four-year licensing agreement with HumaScan of Cranford, NJ. By ending its deal with HumaScan, Scantek regains the rights to market and sell its BreastAlert Differential Temperature Sensor device in the U.S. and Canada.
The move came after HumaScan failed to pay Scantek licensing fees and royalties for BreastAlert, according to Scantek. HumaScan also ran into trouble with the Food and Drug Administration last year, which issued a warning letter regarding the companys marketing tactics (SCAN 6/10/98).
Scantek developed BreastAlert to measure differences in temperature between breasts to detect breast disease as an adjunct to conventional mammography. Perhaps due to the novelty of the system, HumaScan has had difficulty winning acceptance for the product in the U.S. since sales began in early 1998.
Both companies agreed to settle their dispute by ending the licensing agreement. To cancel its $750,000 debt to Scantek, HumaScan transferred its BreastAlert assets to Scantek, including product hardware, software, equipment, and raw materials. Scantek paid $340,000 to HumaScan for other BreastAlert assets that were not included in HumaScans debt, and for 150,000 shares of HumaScan common stock.
With marketing rights firmly in hand, Scantek plans to ramp up its sales efforts in South America and to initiate marketing operations in Ireland, the U.K., Italy, Spain, and Portugal. It hopes to finalize distribution agreements for the majority of these areas in the second quarter of this year. Over the next 10 to 12 months, Scantek will work to establish marketing networks in the U.S., focusing on physician education and support for BreastAlert.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.